Vitamin-D neutralizing CYP24A1 gene expression in thyroid fine-needle aspiration biopsy samples

Balla B1, Horváth P1, Tobiás B1, Győri G2, Járai B3, Kós J4 and Lakatos P4

1 PentaCore Laboratory, Semmelweis University, 2 Department of Radiology and Oncotherapy, Semmelweis University, 3 2nd Dept. of Pathology, Semmelweis University, 4 1st Dept. of Internal Medicine, Semmelweis University, Budapest, Hungary

Abstract

Objectives: We previously published the result of 24-hydroxylase (CYP24A1) gene expression in one hundred, solely papillary thyroid carcinoma (PTC) compared to its own tumor free control from the same patient. We report an increase in CYP24A1 gene transcription in more than half of analyzed PTCs. Elevated CYP24A1 protein expression was also observed in the cancerous tissue section compared to peritumoral normal thyroid tissue. In the present study, we aimed to examine CYP24A1 gene transcription in thyroid fine-needle aspiration biopsy (FNAB) specimens and follow up the patients for two years.

Methods: The gene expression analyses of forty-two thyroid FNABs were carried out by Taqman probe-based quantitative real-time PCR. The somatic mutation status of BRAF, NRAS, HRAS, KRAS oncogenes as well as ELE1/RET and CCD6/RET rearrangements were also tested. genomic DNA and total RNA were isolated from each sample using Roche High Pure kits.

Results: Eight males and 34 females participated in the study. The mean age was 51.43 years. Cytology results of 28 FNABs were benign and 14 were malignant. Within the malignant specimens, 13 papillary and 1 follicular type carcinoma were recognized. Altogether, 6 BRAF (n=113448002) mutations, 1 ELE1/RET translocation were detected in the malignant FNAB samples and one benign biopsy carried HRAS (n=28393406) mutation. CYP24A1 gene expressions were noticed only in five FNAB samples diagnosed with PTC. We could not determine CYP24A1 specific mRNA in the benign samples. During the follow up period we identified malignant transformation in three cases from the 28 initially cytological benign FNABs. In all of these three cases PTC were certified.

Conclusion: It is well established, that CYP24A1 gene activity is elevated in various cancers including thyroid carcinoma might be to protect tumor tissue from the anti-proliferative and pro-apoptotic effects of 1,25-vitamin D3. Our results show that changes of CYP24A1 gene expression have no predictive value in precancerous states of thyroid and it could not help to complete the diagnosis of FNAB cytology.

Introduction

Nowadays, it is well known that key players of vitamin-D metabolism show altered expression in various types of thyroid cancers.

- Work of Clincsopor I. et al. (J Histchem Cytochem 2012;60) indicated enhanced vitamin-D receptor (VDR), CYP27B1 and CYP24A1 (respectively activating and catabolizing vitamin-D) expression in differentiated thyroid cancers compared with normal thyroid. However, papillary carcinoma (PTC) with lymph node metastasis was characterized by lower VDR and CYP24A1 transcribed than non-metastasized PTC.
- Zou M. et al. (J Intern Med 2014;9) reported up-regulated CYP24A1 expression in PTC compared to benign multinodular goitre. The expression was further increased in advanced tumor stages. There was a strong correlation between CYP24A1 overexpression and BRAFV600E mutation.
- We previously published the result of vitamin-D neutralizing 24-hydroxylase (CYP24A1) gene expression in one hundred, solely papillary thyroid carcinoma (PTC) compared to its own tumor free control from the same patient (Balla B. et al J Endocrin Invest 2014). We report an increase in CYP24A1 gene transcription in more than half of analyzed PTCs. We also found association between higher CYP24A1 expression rate and the occurrence of point mutations in oncogenic tumor markers (BRAF, HRAS, CCD6/RET) as well as tumor malignity in a multiparametric method.
- We observed elevated CYP24A1 protein expression in the cancerous tissue section compared to peritumoral normal thyroid tissue.

- Although, vitamin-D signaling and the expression of CYP24A1 are widely investigated in histologically confirmed malignant thyroid conditions. We aimed to examine CYP24A1 gene transcription in thyroid fine-needle aspiration biopsy specimens as a prediction marker and follow up the patients for two years.

Materials & Methods

Study population: Ultrasound-guided thyroid FNAB sampling was carried out in forty-two Hungarian patients. The FNA biopsy sample was dispensed into 1x phosphate buffered saline (PBS) solution and stored at -80°C until nucleic acid extraction. The study was approved by the Regional Committee of Science and Research Ethics, Semmelweis University (SOTE-TUKUB 1160-0/2015-1010EKU).

Somatic oncogenic mutation and rearrangement analysis: Genomic DNA was isolated using Roche High Pure PCR template Preparation Kit according to the manufacturer’s protocol. DNA was tested for BRAF codon 600, HRAS codon 61, KRAS codons 12, 13, and NRAS codon 61 using real-time PCR and fluorescence melting curve analysis (Roche Light Cycler 2.0 Instrument). ELE1/RET, CCD6/RET rearrangements were detected on RNA by RT-PCR ABI Prism 7500 with primers designed to flank the respective fusion point.

Gene expression analysis: Total RNA was isolated from each sample with Roche High Pure Total RNA Isolation kit according to the manufacturer’s recommendations. 500 ng of total RNA was reverse-transcribed to cDNA. The expression of the selected CYP24A1 genes (D: HS00167999_m1; Applied Biosystems) was analyzed by Taqman probe-based quantitative real-time PCR. GAPDH (ID: HS9999905_m1) was used as an endogenous control.

Results

Basic characteristics of patients

<table>
<thead>
<tr>
<th></th>
<th>Patients</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Mean ± SD)</td>
<td>51.43 ± 9.99 years</td>
<td>50.13 ± 9.99 years</td>
<td>51.74 ± 14.59 years</td>
</tr>
</tbody>
</table>

Aspiration cytology sample results

<table>
<thead>
<tr>
<th></th>
<th>FNAB samples</th>
<th>HRAS</th>
<th>KRAS</th>
<th>NRAS</th>
<th>ELE1/RET</th>
<th>CCD6/RET</th>
<th>CYP24A1 expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benign</td>
<td>n = 28</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Malignant</td>
<td>n = 14</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

Summary & Discussion

- The tumor cell growth-inhibiting role of the active metabolite of vitamin-D has been extensively studied in different malignancies. It is well established, that neutralizing CYP24A1 gene activity is elevated in various cancers including thyroid carcinoma might be to protect tumor tissue from the anti-proliferative and pro-apoptotic effects of 1,25-vitamin-D3.
- In this study we could determine very weak CYP24A1 expression in thyroid FNAB samples, solely in patients with cytologically malignant result.
- Our findings show that changes of CYP24A1 gene expression have no predictive value in precancerous states of thyroid and it could not help to complete the diagnosis of FNAB cytology.